NOT-TR-14-005: Notice of National Cancer Institute (NCI) and National Heart, Lung, and Blood Institute (NHLBI) Participation in PAR-14-210 "Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)"

Notice of National Cancer Institute (NCI) and National Heart, Lung, and Blood Institute (NHLBI) Participation in PAR-14-210 "Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)"

Notice Number: NOT-TR-14-005

Key Dates
Release Date: June 3, 2014

Related Announcements
PAR-14-210

Issued by
National Center for Advancing Translational Sciences (NCATS)
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI) are participating, effective immediately, in: PAR-14-210 "Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)".

The following sections of PAR-14-210 have been updated to reflect the participation of NCI and NHLBI in this funding opportunity announcement.

Part 1. Overview Information

Components of Participating Organizations
National Center for Advancing Translational Sciences (NCATS)
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)

Catalog of Federal Domestic Assistance (CFDA) Numbers
93.350, 93.867, 93.866, 93.273, 93.865, 93.279, 93.173, 93.121, 93.242, 93.853, 93.103, 93.395, 93.837, 93.838, 93.839

Part 2. Section I. Research Areas of Interest

National Cancer Institute (NCI)
NCI will consider funding projects consistent with its mission of advancing innovative therapies to benefit patients with cancer.

National Heart, Lung, and Blood Institute (NHLBI)
NHLBI will consider funding projects consistent with its mission of reducing the burden of heart, lung, sleep, and blood conditions and disorders.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact
Barbara Mroczkowski, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-496-4291
Email: [email protected]

John W. Thomas, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0065
Email: [email protected]

Patricia J. Noel, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: [email protected]

Simhan Danthi, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-451-5170
Email: [email protected]

Financial/Grants Management Contact
Garcia Nelson
National Cancer Institute (NCI)
Telephone: 240-276-5613
Email: [email protected]

Kimberly Stanton
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0166
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Christine Colvis, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-451-3903
Email: [email protected]